title: Non-immunosuppressive cyclosporine derivative PSC 833 abolishes resistance of human multidrug-resistant ovarian carcinoma cells in vitro to paclitaxel and paclitaxel-induced radiosensitization.
authors.forename: B
authors.initials: B
authors.lastname: Chorvath
authors.forename: J
authors.initials: J
authors.lastname: Sedlak
authors.forename: L
authors.initials: L
authors.lastname: Novotny
authors.forename: L
authors.initials: L
authors.lastname: Hunakova
authors.forename: E
authors.initials: E
authors.lastname: Boljesikova
authors.forename: L
authors.initials: L
authors.lastname: Sevcikova
authors.forename: M
authors.initials: M
authors.lastname: Chorvath
mesh_terms: D002277:Carcinoma / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D003524:Cyclosporins / Q000008:administration & dosage / Q000494:pharmacology*; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000378:metabolism*; D017239:Paclitaxel / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D003524:Cyclosporins; D011838:Radiation-Sensitizing Agents; D017239:Paclitaxel; C070272:valspodar